JP2021513540A - 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 - Google Patents

抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 Download PDF

Info

Publication number
JP2021513540A
JP2021513540A JP2020542952A JP2020542952A JP2021513540A JP 2021513540 A JP2021513540 A JP 2021513540A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2021513540 A JP2021513540 A JP 2021513540A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513540A5 (https=
JPWO2019160755A5 (https=
Inventor
ララ，マリカ
ジェイン，ロケッシュ
リー，モンヤオ
アルトゥーラ，レイチェル・アリソン
ツエ，アーチー・ガイ−チウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2021513540A publication Critical patent/JP2021513540A/ja
Publication of JP2021513540A5 publication Critical patent/JP2021513540A5/ja
Publication of JPWO2019160755A5 publication Critical patent/JPWO2019160755A5/ja
Priority to JP2024000161A priority Critical patent/JP2024038250A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020542952A 2018-02-13 2019-02-08 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 Pending JP2021513540A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000161A JP2024038250A (ja) 2018-02-13 2024-01-04 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US62/630,038 2018-02-13
US201862732828P 2018-09-18 2018-09-18
US62/732,828 2018-09-18
US201862740741P 2018-10-03 2018-10-03
US62/740,741 2018-10-03
PCT/US2019/017188 WO2019160755A1 (en) 2018-02-13 2019-02-08 Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000161A Division JP2024038250A (ja) 2018-02-13 2024-01-04 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Publications (3)

Publication Number Publication Date
JP2021513540A true JP2021513540A (ja) 2021-05-27
JP2021513540A5 JP2021513540A5 (https=) 2022-09-08
JPWO2019160755A5 JPWO2019160755A5 (https=) 2022-09-08

Family

ID=67620098

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542952A Pending JP2021513540A (ja) 2018-02-13 2019-02-08 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
JP2024000161A Withdrawn JP2024038250A (ja) 2018-02-13 2024-01-04 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000161A Withdrawn JP2024038250A (ja) 2018-02-13 2024-01-04 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Country Status (11)

Country Link
US (1) US20210047409A1 (https=)
EP (1) EP3752193A4 (https=)
JP (2) JP2021513540A (https=)
KR (1) KR20200119845A (https=)
CN (2) CN119792515A (https=)
AU (2) AU2019222517A1 (https=)
BR (1) BR112020015915A8 (https=)
CA (1) CA3090996A1 (https=)
MA (1) MA51844A (https=)
MX (1) MX2020008446A (https=)
WO (1) WO2019160755A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
EP3937979A4 (en) * 2019-03-13 2023-03-08 Merck Sharp & Dohme LLC COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
EP4114863A4 (en) * 2020-03-05 2024-04-24 Merck Sharp & Dohme LLC METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY
EP4114464A4 (en) * 2020-03-05 2024-05-01 Merck Sharp & Dohme LLC Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
MX2024000406A (es) * 2021-07-19 2024-04-18 Regeneron Pharma Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
CN118176021A (zh) * 2021-10-29 2024-06-11 昂科医药 抗ctla-4抗体给药方案
CN113933520B (zh) * 2021-11-15 2023-06-20 邹灵龙 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2024055005A2 (en) * 2022-09-09 2024-03-14 Adagene Pte. Ltd. Activatable anti-ctla4 antibodies for treating cancer
AU2024251723A1 (en) * 2023-04-10 2025-11-27 Akeso Pharma Co., Ltd. Medical use of anti-ctla4 and anti-pd-1 bispecific antibody
WO2025042997A1 (en) * 2023-08-21 2025-02-27 Agenus Inc. Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor
CN121712807A (zh) * 2023-08-31 2026-03-20 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术（上海）股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2017523807A (ja) * 2014-08-01 2017-08-24 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
JP2017530950A (ja) * 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
WO2017210624A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
JP2018522887A (ja) * 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331919A1 (en) * 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US10358496B2 (en) * 2016-03-01 2019-07-23 Ralf Kleef Low dose immune checkpoint blockade in metastatic cancer
LT3463457T (lt) * 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą
WO2017210637A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
SG11201910134SA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523807A (ja) * 2014-08-01 2017-08-24 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
JP2017530950A (ja) * 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2017210624A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., 2017, VOL.77(13-SUPPLEMENT), CT065, JPN6022051032, ISSN: 0005318765 *
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, VOL.12, NO.11, PP.2777-2789, JPN6022051030, ISSN: 0005318766 *
JOUNAL OF IMMUNOTHERAPY OF CANCER, 2017, VOL.5, NO.43, PP.1-9, JPN6022051028, ISSN: 0005318764 *

Also Published As

Publication number Publication date
MA51844A (fr) 2021-05-19
CN119792515A (zh) 2025-04-11
WO2019160755A1 (en) 2019-08-22
BR112020015915A2 (pt) 2020-12-15
KR20200119845A (ko) 2020-10-20
EP3752193A4 (en) 2022-02-23
US20210047409A1 (en) 2021-02-18
RU2020129075A (ru) 2022-03-14
AU2019222517A1 (en) 2020-08-13
JP2024038250A (ja) 2024-03-19
CN111727056A (zh) 2020-09-29
MX2020008446A (es) 2020-09-28
EP3752193A1 (en) 2020-12-23
BR112020015915A8 (pt) 2023-01-31
AU2023208115A1 (en) 2024-01-18
CA3090996A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
JP2021513540A (ja) 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
JP6812512B2 (ja) 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
US20240026003A1 (en) Methods for treating cancer with anti-pd-1 antibodies
JP6586087B2 (ja) Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
EP4114464A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof
EP4136112A1 (en) Combination treatment for cancer
KR20210088640A (ko) 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법
JP2024513247A (ja) 抗ｐｄ－１抗体の皮下投与によるがんの治療方法
RU2825835C2 (ru) Способы лечения рака с помощью анти-PD-1-антител и анти-CTLA4-антител
RU2846266C2 (ru) Способы лечения злокачественного новообразования с использованием антител против pd-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240228

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240510